Estudo randomizado de fase 2 | Pertuzumabe neoadjuvante de-escalonado adicionado à terapia com trastuzumabe com ou sem paclitaxel semanal no câncer de mama inicial, HER2-positivo e hormônio receptor-negativo.

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial – The Lancet Oncology (link para o resumo –$ para o texto completo)